LOGO
LOGO

Will PGN-EDODM1 Deliver Another Win For PepGen In Myotonic Dystrophy Type 1?

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
freedomresults 07012026 lt

Myotonic dystrophy type 1 (DM1) is an inherited, progressive disease that mainly affects the muscles, heart, and nervous system. It occurs in about 1 in 8,000 people worldwide, with roughly 40,000 patients in the United States, 75,000 in Europe, and 15,000 in Japan. Mis-splicing of many important genes is said to be the underlying cause of DM1.

People with DM1 endure muscle stiffness (myotonia), muscle weakness, heart and breathing problems, fatigue, digestive issues, early cataracts, and difficulties with thinking or behaviour. In more severe cases, DM1 can shorten life expectancy, mainly because of heart and lung complications. There are no approved drugs for this rare genetic disorder.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update -June 15 - June 19, 2026

June 19, 2026 16:46 ET
Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.